Analytical Validation of an Immunohistochemical 7-Biomarker Prognostic Assay (immunoprint

7-marker signature prognostic assay (immunoprint®) analytical validation concordance cutaneous melanoma immunohistochemistry reliability repeatability reproducibility risk stratification

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
29 Sep 2023
Historique:
received: 18 09 2023
accepted: 25 09 2023
medline: 14 10 2023
pubmed: 14 10 2023
entrez: 14 10 2023
Statut: epublish

Résumé

Selected patients with early-stage melanoma have a "hidden high risk" of poor oncologic outcomes. They might benefit from clinical trials, and ultimately, if warranted by trial results, judicious everyday use of adjuvant therapy. A promising tool to identify these individuals is the immunoprint

Identifiants

pubmed: 37835839
pii: diagnostics13193096
doi: 10.3390/diagnostics13193096
pmc: PMC10572486
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Synvie GmbH
ID : not applicable (no grant number)

Références

Eur J Cancer. 2023 Mar;182:77-86
pubmed: 36753835
Anal Quant Cytol Histol. 1996 Oct;18(5):351-4
pubmed: 8908306
Histopathology. 2006 Jun;48(7):787-94
pubmed: 16722926
J Invest Dermatol. 2015 Apr;135(4):1190-1193
pubmed: 25330295
J Clin Oncol. 1999 May;17(5):1650
pubmed: 10334562
BMC Cancer. 2019 Mar 20;19(1):249
pubmed: 30894144
J Clin Pathol. 1999 Jan;52(1):75-7
pubmed: 10343618
Eur J Cancer. 2019 Sep;119:18-29
pubmed: 31401470
J Clin Oncol. 2022 Nov 10;40(32):3741-3749
pubmed: 35709414
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
PLoS One. 2012;7(6):e38222
pubmed: 22685558
Lancet Oncol. 2021 May;22(5):643-654
pubmed: 33857412
Acta Derm Venereol. 2021 Jul 15;101(7):adv00502
pubmed: 34003298
J Am Acad Dermatol. 2017 Feb;76(2):258-263
pubmed: 27887797
J Clin Med. 2022 Apr 05;11(7):
pubmed: 35407631
Arch Pathol Lab Med. 2014 Nov;138(11):1432-43
pubmed: 24646069
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
J Surg Oncol. 2020 Dec;122(8):1770-1777
pubmed: 33098702
Cancers (Basel). 2021 Jun 10;13(12):
pubmed: 34200680
Ann Surg Oncol. 2019 Jul;26(7):2254-2262
pubmed: 31011906
J Invest Dermatol. 2010 Mar;130(3):793-7
pubmed: 19829301

Auteurs

Mirjana Ziemer (M)

Department of Dermatology, Allergology and Venereology, University Medical Center, 04103 Leipzig, Germany.

Beate Weidenthaler-Barth (B)

Department of Dermatology, University Medical Center Mainz, 55131 Mainz, Germany.

Philipp Gussek (P)

Department of Dermatology, Allergology and Venereology, University Medical Center, 04103 Leipzig, Germany.

Maja Pfeiffer (M)

Department of Dermatology, University Medical Center Mainz, 55131 Mainz, Germany.

Johannes Kleemann (J)

Department of Dermatology, Venerology and Allergology, University Hospital Frankfurt, Goethe University, 60590 Frankfurt am Main, Germany.

Katrin Bankov (K)

Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Goethe University, 60590 Frankfurt am Main, Germany.

Peter J Wild (PJ)

Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Goethe University, 60590 Frankfurt am Main, Germany.
Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Germany.

Silke Seibold (S)

Synvie GmbH, 80992 Munich, Germany.

Priyavathi Sureshkumar (P)

Synvie GmbH, 80992 Munich, Germany.

Patricia Nickel (P)

Synvie GmbH, 80992 Munich, Germany.

Anton Strobel (A)

Synvie GmbH, 80992 Munich, Germany.

Markus Werner (M)

Synvie GmbH, 80992 Munich, Germany.

Stephan Grabbe (S)

Department of Dermatology, University Medical Center Mainz, 55131 Mainz, Germany.

Classifications MeSH